PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.

MLA

Blons, H., et al. “PTEN, ATM, IDH1 Mutations and MAPK Pathway Activation as Modulators of PFS and OS in Patients Treated by First Line EGFR TKI, an Ancillary Study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France Project.” Lung Cancer (Amsterdam, Netherlands), vol. 151, Jan. 2021, pp. 69–75. EBSCOhost, https://doi.org/10.1016/j.lungcan.2020.11.008.

APA

Blons, H., Oudart, J.-B., Merlio, J.-P., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P.-P., Fraboulet-Moreau, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A., Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., & Beau-Faller, M. (2021). PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer (Amsterdam, Netherlands), 151, 69–75. https://doi.org/10.1016/j.lungcan.2020.11.008

Chicago

Blons, H, J-B Oudart, J-P Merlio, D Debieuvre, F de Fraipont, C Audigier-Valette, F Escande, et al. 2021. “PTEN, ATM, IDH1 Mutations and MAPK Pathway Activation as Modulators of PFS and OS in Patients Treated by First Line EGFR TKI, an Ancillary Study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France Project.” Lung Cancer (Amsterdam, Netherlands) 151 (January): 69–75. doi:10.1016/j.lungcan.2020.11.008.